Bruker Corporation (NASDAQ:BRKR) had its target price upped by research analysts at Citigroup Inc. from $29.00 to $34.00 in a research report issued to clients and investors on Friday. The firm currently has a “neutral” rating on the medical research company’s stock. Citigroup Inc.’s price objective would indicate a potential upside of 1.98% from the company’s current price.

A number of other analysts have also recently commented on BRKR. Bank of America Corporation upgraded shares of Bruker Corporation from an “underperform” rating to a “neutral” rating and set a $34.00 price target for the company in a research note on Friday. BidaskClub cut shares of Bruker Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, August 9th. Cowen and Company reiterated a “hold” rating and issued a $29.00 price target on shares of Bruker Corporation in a research note on Friday. J P Morgan Chase & Co upgraded shares of Bruker Corporation from an “underweight” rating to a “neutral” rating and set a $28.00 price target for the company in a research note on Friday. Finally, Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and issued a $24.00 price target on shares of Bruker Corporation in a research note on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $28.58.

Shares of Bruker Corporation (NASDAQ:BRKR) traded up $1.45 during mid-day trading on Friday, reaching $33.34. 2,025,227 shares of the company’s stock were exchanged, compared to its average volume of 444,070. The stock has a market cap of $4.96 billion, a price-to-earnings ratio of 26.75 and a beta of 1.05.

Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.02. The firm had revenue of $435.60 million during the quarter, compared to analysts’ expectations of $415.45 million. Bruker Corporation had a net margin of 8.85% and a return on equity of 25.93%. The company’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.32 earnings per share. research analysts expect that Bruker Corporation will post 1.12 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.watchlistnews.com/citigroup-inc-boosts-bruker-corporation-brkr-price-target-to-34-00/1676638.html.

In related news, VP Mark Munch sold 21,061 shares of the firm’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $29.97, for a total transaction of $631,198.17. Following the transaction, the vice president now directly owns 60,524 shares of the company’s stock, valued at $1,813,904.28. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Frank H. Laukien purchased 2,335 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were acquired at an average cost of $27.39 per share, for a total transaction of $63,955.65. Following the completion of the transaction, the chief executive officer now owns 37,791,386 shares of the company’s stock, valued at approximately $1,035,106,062.54. The disclosure for this purchase can be found here. Company insiders own 35.20% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in BRKR. Acrospire Investment Management LLC increased its position in Bruker Corporation by 496.1% during the second quarter. Acrospire Investment Management LLC now owns 3,827 shares of the medical research company’s stock worth $110,000 after acquiring an additional 3,185 shares during the period. SG Americas Securities LLC bought a new position in Bruker Corporation during the second quarter worth about $111,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Bruker Corporation by 11.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,599 shares of the medical research company’s stock worth $133,000 after acquiring an additional 467 shares during the period. Smithfield Trust Co. bought a new position in Bruker Corporation during the second quarter worth about $138,000. Finally, The Manufacturers Life Insurance Company increased its position in Bruker Corporation by 7.1% during the second quarter. The Manufacturers Life Insurance Company now owns 5,003 shares of the medical research company’s stock worth $144,000 after acquiring an additional 331 shares during the period. 65.74% of the stock is currently owned by institutional investors and hedge funds.

About Bruker Corporation

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Analyst Recommendations for Bruker Corporation (NASDAQ:BRKR)

Receive News & Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.